Kythera's injectable deoxycholic acid-based drug reduced submental fat better than placebo in two Phase III clinical trials, the company announced.
Published in Brief:
|Compliance and Ethics Director||
Sysmex America, Inc.
|Director, Site Quality Management||
|Palm Springs, CA|
|Compliance Officer-Medical Products||
W. L. Gore